Regent Pacific Group Limited — Capital/Financing Update 2018

Feb 13, 2018

==> picture [512 x 73] intentionally omitted <==

==> picture [113 x 644] intentionally omitted <==

(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575 13 February 2018

ANNOUNCEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FORTACIN™ UPDATE EUROPEAN LAUNCH COMMENCED

SUMMARY

This announcement is made by the Company in compliance with the disclosure requirements under Rule 13.09 of the HK Listing Rules and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Directors of the Company are delighted to inform the shareholders of the Company and potential investors that Recordati informed the Company on 12 February 2018 that Fortacin™ was officially launched, by way of first commercial sales from Recordati, the Group’s commercial partner, to wholesalers in Italy on 9 February 2018, with first Fortacin™ sales expected to follow in France and Spain on 16 and 19 February 2018, respectively, and thereafter in Germany and Portugal on 1 March 2018.

It now follows that, following the first commercial sale of Fortacin™ in each of France, Germany, Italy, Portugal and Spain, a total of €4 million (or approximately US$4.91 million or HK$38.30 million) will be due from Recordati to the Group, without any withholding as the three manufactured batches at 300 litre scale have come back within specification, as previously reported.

==> picture [512 x 47] intentionally omitted <==

==> picture [513 x 44] intentionally omitted <==

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Regent Pacific Group Limited (the “ Company ” and collectively with its subsidiaries, the “ Group ”) in compliance with the disclosure requirements under Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ HK Listing Rules ”) and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The directors (the “ Directors ” or the “ Board ”) of the Company are delighted to inform the shareholders of the Company and potential investors that Recordati S.p.A. (“ Recordati ”), the Group’s commercial partner, informed the Company on 12 February 2018 that Fortacin™ was officially launched, by way of first commercial sales from Recordati to wholesalers in Italy on 9 February 2018, with first Fortacin™ sales expected to follow in France and Spain on 16 and 19 February 2018, respectively, and thereafter in Germany and Portugal on 1 March 2018.

It now follows that, following the first commercial sale of Fortacin™ in each of France, Germany, Italy, Portugal and Spain, a total of €4 million (or approximately US$4.91 million or HK$38.30 million) will be due from Recordati to the Group, without any withholding as the three manufactured batches at 300 litre scale have come back within specification, as previously reported.

The Directors are also pleased to report that Recordati remains confident that the planned commercialisation of Fortacin™ in Greece, Romania, Czech Republic, Slovak Republic and Poland in the second half of 2018 remains on schedule with commercialisation efforts to target the rest of Europe, Russia, the Commonwealth of Independent States (CIS) and select countries of North Africa in the coming years.

The Group is continuing to make progress with the Hong Kong Department of Health Drug Office and the Macau Government Health Bureau to acquire import licences to allow for the sale of Fortacin™ in Hong Kong and Macau and remains in active discussions with possible commercial partners for the sale and distribution of Fortacin™ in the remaining key markets of China, North America, Latin America and the Asia Pacific regions.

==> picture [512 x 24] intentionally omitted <==

Page 2 of 3

==> picture [513 x 44] intentionally omitted <==

The Group will continue to work closely and diligently with its commercial partners and will keep shareholders and potential investors informed of any new developments as and when they occur.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

• Note: Unless otherwise specified herein, amounts denominated in: (i) EUR have been translated, for the purpose of illustration only, into US$ using the exchange rate of EUR 1.00 = US$1.2275; and (ii) US$ have been translated, for the purpose of illustration only, into HK$ using the exchange rate of US$1.00 = HK$7.80.

On Behalf of the Board of Regent Pacific Group Limited

Jamie Gibson Director

Directors of the Company : James Mellon (Chairman)[*]

Jamie Gibson (Chief Executive Officer) David Comba[#] Julie Oates[#] Mark Searle[#] Jayne Sutcliffe[*]

• Non-Executive Directors

# Independent Non-Executive Directors

Hong Kong, 13 February 2018

==> picture [512 x 24] intentionally omitted <==

Page 3 of 3